Ranbaxy Wants In On Mylan's Suit Over Valsartan Exclusivity

Law360, New York (October 15, 2012, 3:21 PM EDT) -- Ranbaxy Laboratories Ltd. on Friday asked a Washington federal court to allow it to intervene in a Mylan Pharmaceuticals Inc. generic exclusivity dispute with the U.S. Food and Drug Administration over hypertension drug valsartan, saying only it could properly defend its exclusive rights to the drug.

According to the drugmaker’s motion to intervene in the suit, brought by Mylan on Oct. 2, it was the first company to file an abbreviated new drug application with the FDA to manufacture generic valsartan, meaning it was entitled to...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

MYLAN LABORATORIES LIMITED et al v. FOOD AND DRUG ADMINISTRATION et al


Case Number

1:12-cv-01637

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

John D. Bates

Date Filed

October 2, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.